Basal Cell Carcinoma

P3, N=142, Recruiting, University of Sao Paulo

This review integrates the histopathological, molecular, and emerging spatial transcriptomic insights across this spectrum of rare and treatment-resistant prostate cancer subtypes. By highlighting shared mechanisms such as genomic instability, androgen receptor (AR) pathway bypass, and microenvironmental remodeling, we outline key diagnostic considerations and evolving therapeutic implications relevant to precision oncology.

Management algorithms are increasingly multidisciplinary, integrating ophthalmology, dermatology, oncology, pathology, and reconstructive surgery. Ongoing challenges include timely detection, management of adverse effects, and the risk of recurrence and metastasis, necessitating long-term surveillance and individualised care.

Chemoprevention (e.g., nicotinamide) and targeted therapies (hedgehog inhibitors; Programmed Death-1 blockade) represent key translational levers for care innovation. (5) Integrating structured dermatologic surveillance with molecularly informed prevention and therapy should be standard in survivorship pathways for hematopoietic stem cell transplantation/Radiotherapy-exposed patients.

The transitional zone and uninvolved skin contained CD34-positive fibroblast-like cells situated between secondary bundles of reticular dermis, as well as CD34-positive cell processes within these bundles. The observed pattern of CD34 positivity within the examined regions shows a specific distribution, providing insight into the adaptive responses of the skin to the tumoral process.

P2, N=60, Active, not recruiting, Highlight Therapeutics | Recruiting --> Active, not recruiting

Combined use of LEF1 and β-catenin improved sensitivity (90%) but resulted in a medium specificity (93%). In conclusion, the proposed immunohistochemical panel can improve diagnostic accuracy in basaloid tumors of the salivary glands.

P3, N=1630, Not yet recruiting, VA Office of Research and Development | Trial completion date: Jan 2032 --> May 2032 | Trial primary completion date: Jan 2032 --> May 2032

P=N/A, N=30, Not yet recruiting, Henry Ford Health System

Taken together, our findings reveal that aging affects tumor-associated vasculature but not BCC formation or regression in our model. These results are in keeping with the notion that a major contributor to the increased incidence of BCCs in elderly patients is the accumulation of oncogenic driver mutations over time rather than intrinsic changes in aged skin that promote BCC tumorigenesis.

P1, N=97, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed

In this review, we summarize advances in our understanding of Hh-mediated cell death in gastrointestinal cancers and the role and mechanisms, and highlight the underlying therapeutic opportunities. These new findings advance the rapidly expanding field of translational cancer research focused on the Hh signaling pathway.